Takeda Pharmaceutical (TAK) Leases (2019)

Takeda Pharmaceutical's (TAK) quarterly Leases came in at $19.2 million in Q1 2019.

Takeda Pharmaceutical (TAK) Leases (2019) Analysis & Trends

Takeda Pharmaceutical's Leases history runs 1 years deep, the most recent figure standing at $19.2 million for Q1 2019.

On a quarterly basis, Leases changed N/A year-over-year to $19.2 million in Q1 2019; TTM through Mar 2019 was $19.2 million, a N/A change from a year earlier, with the FY2019 full-year figure at $19.2 million, changed N/A from the prior year.
Leases was little changed at $19.2 million in Q1 2019 per TAK's latest filing.
Across five years, Leases topped out at $19.2 million in Q1 2019 and bottomed at $19.2 million in Q1 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Leases (Qtr)
1	Haleon	89.24 Bn	87.37 Bn	-	-
2	Teva Pharmaceutical Industries	35.91 Bn	32.17 Bn	1.97 Bn	335.00 Mn
3	Zoetis	32.61 Bn	30.67 Bn	1.62 Bn	282.00 Mn
4	Takeda Pharmaceutical	27.55 Bn	23.49 Bn	4.39 Bn	-
5	United Therapeutics	23.28 Bn	21.13 Bn	648.10 Mn	-
6	RedHill Biopharma	20.54 Bn	20.54 Bn	-	1.06 Mn
7	Viatris	20.31 Bn	18.50 Bn	1.16 Bn	253.00 Mn
8	Neurocrine Biosciences	17.76 Bn	16.44 Bn	800.70 Mn	447.10 Mn
9	Elanco Animal Health	12.55 Bn	12.12 Bn	785.00 Mn	-
10	Vireo Growth	10.52 Bn	10.37 Bn	59.30 Mn	84.80 Mn

Historic Data

Download Data

Date	Value
Mar 31, 2019	19.17 Mn